Sai Parenterals bags ₹1,300 crore Australia OTC deal 2026

Deal sets a long runway for Australia business

Hyderabad-based Sai Parenterals Limited said it has secured a major overseas milestone through its Australia subsidiary, Noumed Pharmaceuticals Pty Limited. Noumed has entered into a fresh supply agreement for OTC medicines with leading pharmacy networks in Australia. The company disclosed the deal value at AUD 202 million, which it approximated at about ₹1,300 crore. The agreement is set to begin on July 1, 2026.

For Sai Parenterals, the contract underlines why the Australia acquisition has become central to its global strategy. The company has positioned Noumed as its last-mile commercial platform in a regulated market, alongside its India-based manufacturing and CDMO operations. The announcement also comes at a time when Sai Parenterals has begun reporting consolidated financials that include Noumed for part of FY26.

Contract duration, extension option, and annual run-rate

Sai Parenterals said the supply contract has an initial term of 7.5 years. Based on the company’s disclosure, the deal works out to an average business of AUD 27 million per year. Using the same conversion implied by the stated deal value (AUD 202 million equals about ₹1,300 crore), this annual run-rate is roughly ₹174 crore per year.

The contract also carries an extension clause. Sai Parenterals said the agreement can be extended by another three years through mutual consent. The company indicated that product expansion is a core part of the contract economics, with a target of adding 12 new products every year under the arrangement.

Noumed’s role: end-to-end OTC supply and compliance

The company said Noumed will continue as an exclusive supplier of OTC pharmaceutical products in the Australian market. Noumed’s responsibilities under the agreement include manufacturing, product sourcing, and ongoing compliance with regulatory requirements. It will also handle TGA registrations, warehousing, quality assurance, and nationwide distribution.

This structure makes Noumed more than a marketing entity. Sai Parenterals is effectively using the Australian subsidiary as a regulatory, supply-chain, and distribution hub, which can reduce execution friction for new launches in Australia, where TGA compliance and dossier readiness are central to speed-to-market.

Management commentary highlights client trust and execution

Sai Parenterals Managing Director Anil Kumar Karusala said the updated agreement reflects the trust placed by leading Australian pharmacy groups in Noumed. Noumed CEO Mark Thulborne said the long-term nature of the contract reflects strong customer relationships and the company’s ability to supply quality products on time.

The company also pointed to its R&D capability as a support function for supplying products across India and international markets. The broader narrative in management commentary is that the group is combining manufacturing scale with regulated-market access, rather than remaining only a contract manufacturer.

Acquisition context: the Noumed deal that changed the playbook

Sai Parenterals highlighted that it acquired a 74.6% controlling stake in Noumed Pharmaceuticals Pty Limited in November 2025. It also stated that the acquisition gives access to 451 product dossiers and strengthens its presence in the Australian pharmaceutical market.

In a separate management interaction, the company described its evolution from domestic manufacturing to regulatory exports, then CDMO, and now to a formulation player with last-mile marketing through Australia. Management also said that the IPO is expected to provide growth capital, and that by the end of 2026-27 it expects to have five regulatory plants, four in Hyderabad and one in Australia, with European GMP approvals.

IP dossier pool and portfolio mix

Management said the dossier base is a key lever for regulated-market expansion. It stated that 451 IP dossiers came with the Australian business and that the company also has 55 IPs in India. It further stated that, in total, 551 IP dossiers are available.

On revenue mix, management stated that, last year, 45% of revenue came from injectables and 55% came from OSDs. It also said that OSD revenues are coming from exports, while injectable revenue is coming from the local branded GeneXus business. In Australia and New Zealand, the business includes complex molecules as well as OTC products.

FY26 financial snapshot after part-year Noumed consolidation

Sai Parenterals ended FY26 as a newly listed company with a larger consolidated footprint after the Noumed acquisition. In Q4FY26, the first full quarter of Noumed consolidation, it reported consolidated revenue of ₹198 crore, EBITDA of ₹29 crore, and PAT of ₹13 crore. For FY26, consolidated revenue from operations was ₹381 crore, with EBITDA of ₹47 crore and PAT of ₹14 crore.

The company noted that the reported FY26 consolidation reflects only a part-year inclusion of Noumed because the acquisition was completed on November 12, 2025, and consolidated from that date.

Capacity expansion, Australia plant, and grant support

The company said it is executing expansion and upgradation across India and Australia, supported by IPO proceeds and additional funding at the subsidiary level. It disclosed that Unit III in India, described as a TGA Australia approved manufacturing facility, is planned to expand capacity from 240 million units to 451 million units, with expected completion in October 2026.

It also said ₹111 crore is being deployed for capacity expansion and EU-GMP upgrades in India, and ₹18 crore for the R&D center, funded through IPO proceeds. Separately, the company outlined an Australia plant investment of AUD 53 million, disclosed at about ₹291.5 crore, and an Australian government grant of AUD 20 million, disclosed at about ₹110 crore. The company also stated that its total planned investment exceeds ₹420 crore, combining ₹118 crore for India, the Australia plant capex, and ₹18 crore for the R&D facility.

Key figures at a glance

Market impact: what investors will track next

The OTC supply agreement materially improves revenue visibility for the Australia platform, because it is structured as a multi-year, exclusive supply arrangement with major pharmacy networks. The annual product-addition plan of 12 new products also indicates that the contract is intended to scale over time, not remain static.

Investors are also likely to watch execution across manufacturing readiness, regulatory filings, and distribution performance, since Noumed is responsible for TGA registrations and nationwide logistics. With the Adelaide manufacturing facility expected to begin commercial operations by the fourth quarter of 2026, the timeline overlaps with the commencement of the new OTC supply contract starting July 1, 2026.

Why this matters: integration and capex become the main story

Sai Parenterals attributed robust quarterly performance to strong CDMO exports and the integration of Noumed. The company also reported a sharp rise in profit for the quarter ended March 2026, stating profit increased 736% to ₹13.25 crore, and linked this improvement to the Australia acquisition.

A board meeting was scheduled for April 20, 2026, with the main agenda item being potential investment or loan funding for Noumed Pharmaceuticals, routed through the company’s Singapore-based subsidiary, Sai Parenterals PTE Limited. Alongside this, the disclosed capex plans across India, R&D, and the Australia facility show that the next phase depends on timely commissioning and regulatory upgrades.

Conclusion

Sai Parenterals’ Noumed-led OTC supply agreement, valued at about ₹1,300 crore over 7.5 years and starting July 1, 2026, strengthens the commercial backbone of its Australia strategy. The company is pairing this with capacity expansion in India, a new Australia facility expected to start commercial operations in Q4 2026, and continued integration after the November 2025 acquisition. The next set of milestones will be tied to funding decisions for the subsidiary, completion of planned capacity upgrades by October 2026, and sustained performance as consolidated numbers reflect a longer period of Noumed’s contribution.